Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tiziana Life Sciences ( (TLSA) ) just unveiled an update.
Tiziana Life Sciences announced positive results from studies using a nasal anti-CD3 monoclonal antibody for treating traumatic spinal cord injury (SCI) as of January 23, 2025. This development highlights significant advancements in motor function among treated models and showcases the potential of Tiziana’s immunomodulation therapies in addressing SCI’s complex neurotraumatic wounds, impacting military personnel, veterans, and the general population. The company is expanding its nasal foralumab technology from multiple sclerosis applications to spinal cord injuries, marking a strategic step towards addressing significant unmet medical needs.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focusing on breakthrough therapies through innovative drug delivery technologies. The company is developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which promises improved efficacy and safety compared to traditional intravenous delivery, and has shown a favorable safety profile in clinical studies.
YTD Price Performance: 30.15%
Average Trading Volume: 650,790
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $97.93M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.
